2 active not recruiting, 2 recruiting, 1 enrolling by invitation, 1 unknown. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 2, Recruiting 2, Enrolling by invitation 1, Unknown 1 |
Follow Exemestane tablets: new trials by email Literature Review of Exemestane tablets trials Research Report on Exemestane tablets
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer HRS-8080 Tablets, Letrozole tablets, Tamoxifen Citrate Tablets - Breast Cancer | Phase 3 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 5500 | 2026-03-04 | 2026-05-22 |
| A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer HRS-8080 Tablet, Fulvestrant injection, Exemestane tablets - Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 240 | 2025-07-23 | 2026-10-02 |
| A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) SIM0270, Everolimus (Afinitor®), Exemestane tablets - Locally Advanced or Metastatic Breast Cancer | Phase 3 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 482 | 2024-11-14 | 2026-08-11 |
| Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study TOL2506, Tamoxifen, Letrozole tablets - Breast Cancer | Phase 3 | Enrolling by invitation | Tolmar Inc. | 250 | 2022-12-28 | 2026-10-23 |
| Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer TOL2506, Tamoxifen, Letrozole Tablets - Breast Cancer | Phase 3 | Active not recruiting | Tolmar Inc. | 250 | 2021-07-01 | 2026-10-23 |
| A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP） Exemestane Tablets, ovarian function suppression/ablation, CYP2D6*10 gene test - CYP2D6 Polymorphism | Phase 3 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 300 | 2018-08-09 | 2018-10-31 |
Breast Neoplasms (6) · Neoplasms (2)
Shandong Suncadia Medicine Co., Ltd. (2) · Tolmar Inc. (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1)
China (4) · Argentina (2) · Brazil (2) · India (2) · Mexico (2) · Puerto Rico (2) · United States (2) · Canada (1)
E P Hamilton (1)
PMID 11972444, PMID 15632378, PMID 16361630, PMID 16959170, PMID 17301689, PMID 18024866, PMID 18407954, PMID 19118028, PMID 20133065, PMID 20809362, PMID 20824020, PMID 21075954, PMID 23570465, PMID 24192122, PMID 24881463, PMID 25495490, PMID 25554091, PMID 25559415, PMID 9741784